Agreements

Date: 2017-07-18

Type of information: Research agreement

Compound: novel bispecific antibodies based on kappa-lambda bispecific antibody technology

Company: Novimmune (Switzerland) Baxalta (USA - IL) now Shire (UK - USA)

Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases

Type agreement: R&D - research

Action mechanism:

bispecific antibody. The kappa-lambda bispecific antibody technology provides a method for producing fully human bispecific antibodies.

Disease: hemophilia A

Details:

• On September 2, 2015, Novimmune announced that it has signed an international research collaboration agreement with Baxalta to develop novel bispecific antibodies for an unspecified indication. This is the first collaboration utilizing Novimmune's new kappa-lambda bispecific antibody technology. The proprietary platform generates fully human antibodies which target two specific binding sites with one antibody.

Financial terms: Financial terms of the deal were not disclosed.

Latest news:

• On July 18, 2017, Shire and Novimmune announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize an innovative, bi-specific antibody in pre-clinical development for the treatment of hemophilia A and hemophilia A patients with inhibitors. Shire is leading the development of the program to optimize and evaluate a fully-human, bi-specific IgG antibody targeting FIXa and FX, designed to imitate the body’s natural mechanism of Factor VIII-driven coagulation. The company’s ultimate aim is to deliver a treatment that improves upon the strong and long-term record of efficacy and safety that has been set by the Factor class.
“Novimmune is building on a collaboration initiated in 2015 with Shire to generate and evaluate Factor VIII-mimetic, bi-specific antibodies,” said Ed Holdener, Chairman and CEO of Novimmune. Novimmune has been developing a platform for making fully human, bi-specific antibodies and has several in-house programs targeting tumor associated antigens and the immune system check point protein CD47.
The specific terms of this deal were not disclosed.